Hepatitis C Information - MIGENIX initiates enrolment in Phase IIb

MIGENIX initiates enrolment in Phase IIb
InPharm.com - Celgosivir is a first-in-class, orally-administered, alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C (

FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950
PR Newswire - CAMBRIDGE, Mass., Dec. 8 /PRNewswire-FirstCall/ -- Vertex PharmaceuticalsIncorporated (Nasdaq: VRTX) today announced that the U.S. oral hepatitis C virus (